Novel n-7-heterocyclyl pyrrolo2,3-dpyridines and their use
CA 2249739 A1 · Owner: Novartis Ag · Inventors: Altmann, Eva
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Described are pyrrolo2,3-dpyrimidines in which R1 to R5 m and n are as , defined in the description. The compounds exhibit useful pharmaceutical properties and are particularly effective as protein tyrosine kinase inhibitors. The can be used to treat bone and other illnesses in warm-blooded animals in which inhibition of protein tyrosine kinase has a favourable effect.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 5, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 5, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 5, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.